Bispecific chimeric antigen receptors targeting CD20 and BCMA

Abstract

The present disclosure provides a bispecific chimeric antigen receptor (CAR) that targets CD20 and BCMA. The CAR may comprise a CD20-targeting scFv, a BCMA-targeting scFv, a hinge region, a transmembrane domain, a costimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptor can be used to treat autoimmune disorders or cancer.

Claims

1. A bispecific chimeric antigen receptor (CAR) comprising an anti-CD20 antigen-binding region and an anti-BCMA antigen-binding region, and comprising the amino acid sequence described in SEQ ID NO:

26.

2. An immune cell comprising the bispecific CAR described in claim 1.

3. The immune cell according to claim 2, wherein the immune cell is a T cell or a natural killer (NK) cell.

4. A nucleic acid encoding a bispecific CAR as described in claim 1.

5. A vector comprising the nucleic acid described in claim 4.

6. A pharmaceutical composition comprising the immune cells described in claim 2.

Images